VCP
AZN icon

Verus Capital Partners’s AstraZeneca AZN Stock Holding History

Verus Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$25K Hold
275
– – 0.01% 714
2019
Q4 		$27K Buy
+275
New +$25.9K 0.01% 776

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verus Capital Partners's AZN Position: Q1 2020 in Review

Verus Capital Partners held its AstraZeneca (AZN) position steady in Q1 2020 at 275 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #714.

Verus Capital Partners first reported a position in AZN in Q4 2019 and has held it in 2 quarters since. The position peaked at $27K in Q4 2019. 603 funds tracked by Wall St. Rank hold AZN as of Q1 2020.

  • Verus Capital Partners held 275 shares of AstraZeneca worth $25K as of Q1 2020.
  • Verus Capital Partners left its AstraZeneca share count unchanged in Q1 2020.
  • AstraZeneca made up 0.01% of Verus Capital Partners's portfolio in Q1 2020, its #714 holding.
  • Verus Capital Partners first reported a position in AstraZeneca in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's AstraZeneca position peaked at $27K in Q4 2019.
  • 603 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.